my country has approved the issuance of 6 national first-class standard substances for tumor gene testing

On 31/03/2025, the State Administration for Market Regulation (SAMR) issued an update regarding "my country has approved the issuance of 6 national first-class standard substances for tumor gene testing". These standards fill a gap in China's substance standards for tumor molecular diagnosis, enhancing the accuracy and comparability of genetic test results. They provide reliable technical support for early cancer detection, individualized treatment plans, and patient health protection.